NK cell-intrinsic FcεRIγ limits CD8+ T-cell expansion and thereby turns an acute into a chronic viral infection.
Acute Disease
Animals
Antigens, Ly
/ genetics
CD8-Positive T-Lymphocytes
/ immunology
Chronic Disease
Killer Cells, Natural
/ immunology
Lymphocyte Activation
Lymphocytic Choriomeningitis
/ genetics
Lymphocytic choriomeningitis virus
/ immunology
Mice
Mice, Knockout
Natural Cytotoxicity Triggering Receptor 1
/ genetics
Receptors, Fc
/ genetics
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
27
08
2018
accepted:
29
04
2019
revised:
02
07
2019
pubmed:
21
6
2019
medline:
4
12
2019
entrez:
21
6
2019
Statut:
epublish
Résumé
During viral infection, tight regulation of CD8+ T-cell functions determines the outcome of the disease. Recently, others and we determined that the natural killer (NK) cells kill hyperproliferative CD8+ T cells in the context of viral infection, but molecules that are involved in shaping the regulatory capability of NK cells remain virtually unknown. Here we used mice lacking the Fc-receptor common gamma chain (FcRγ, FcεRIγ, Fcer1g-/- mice) to determine the role of Fc-receptor and NK-receptor signaling in the process of CD8+ T-cell regulation. We found that the lack of FcRγ on NK cells limits their ability to restrain virus-specific CD8+ T cells and that the lack of FcRγ in Fcer1g-/- mice leads to enhanced CD8+ T-cell responses and rapid control of the chronic docile strain of the lymphocytic choriomeningitis virus (LCMV). Mechanistically, FcRγ stabilized the expression of NKp46 but not that of other killer cell-activating receptors on NK cells. Although FcRγ did not influence the development or activation of NK cell during LCMV infection, it specifically limited their ability to modulate CD8+ T-cell functions. In conclusion, we determined that FcRγ plays an important role in regulating CD8+ T-cell functions during chronic LCMV infection.
Identifiants
pubmed: 31220194
doi: 10.1371/journal.ppat.1007797
pii: PPATHOGENS-D-18-01662
pmc: PMC6605677
doi:
Substances chimiques
Antigens, Ly
0
Natural Cytotoxicity Triggering Receptor 1
0
Ncr1 protein, mouse
0
Receptors, Fc
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007797Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Mol Biol Evol. 2005 Aug;22(8):1661-72
pubmed: 15872155
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Trends Immunol. 2007 Feb;28(2):66-73
pubmed: 17197236
Oncogene. 2003 Nov 24;22(53):8628-33
pubmed: 14634624
Eur J Immunol. 1999 Mar;29(3):1014-20
pubmed: 10092106
J Immunol. 2001 Jan 1;166(1):21-5
pubmed: 11123272
Ann Hematol. 1998 Jun;76(6):231-48
pubmed: 9692811
Immunology. 2009 Sep;128(1):7-15
pubmed: 19689731
Nat Immunol. 2010 Feb;11(2):121-8
pubmed: 20023661
Nature. 2001 Feb 22;409(6823):1055-60
pubmed: 11234016
Cell Rep. 2018 Mar 27;22(13):3385-3392
pubmed: 29590608
Virology. 2015 May;479-480:180-93
pubmed: 25620767
Blood. 2008 Nov 15;112(10):4109-16
pubmed: 18784374
Annu Rev Immunol. 2003;21:579-628
pubmed: 12500981
Immunol Cell Biol. 2011 Feb;89(2):216-24
pubmed: 20567250
Nature. 2011 Nov 20;481(7381):394-8
pubmed: 22101430
Annu Rev Med. 2018 Jan 29;69:301-318
pubmed: 29414259
Eur J Immunol. 2014 Nov;44(11):3368-79
pubmed: 25100508
J Innate Immun. 2011;3(3):274-9
pubmed: 21411975
Front Immunol. 2012 Jul 05;3:187
pubmed: 22783260
Curr Top Microbiol Immunol. 2002;263:7-27
pubmed: 11987821
Int Immunol. 2012 Dec;24(12):793-802
pubmed: 22962434
Immunity. 2014 Jun 19;40(6):949-60
pubmed: 24909887
Immunity. 2019 Feb 19;50(2):403-417.e4
pubmed: 30709740
Immunity. 2014 Jun 19;40(6):961-73
pubmed: 24909889
Sci Immunol. 2017 Apr 28;2(10):
pubmed: 28480349
Front Immunol. 2013 Mar 20;4:69
pubmed: 23518691
J Immunol. 2013 Jun 15;190(12):6269-76
pubmed: 23656738
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1210-5
pubmed: 22167808
Immunity. 2006 Jul;25(1):19-29
pubmed: 16860754
J Immunol. 2004 Jan 1;172(1):123-9
pubmed: 14688317
J Immunol. 2003 Mar 15;170(6):3054-8
pubmed: 12626560
Immunity. 2016 Aug 16;45(2):225-6
pubmed: 27533005
J Virol Methods. 1991 Jun;33(1-2):191-8
pubmed: 1939506
J Biol Chem. 1990 Apr 15;265(11):6448-52
pubmed: 2138619
Oncoimmunology. 2014 Nov 14;3(8):e948705
pubmed: 25960930
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Cell. 1994 Feb 11;76(3):519-29
pubmed: 8313472
Curr Top Microbiol Immunol. 2016;395:37-61
pubmed: 26305047
Nature. 1994 May 5;369(6475):31-7
pubmed: 8164737
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3384-9
pubmed: 17360655
J Virol. 2009 Aug;83(16):8108-21
pubmed: 19515783
J Immunol. 2013 Jan 15;190(2):641-9
pubmed: 23241878